View Item 

Show simple item record

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders
dc.contributor.authorJensen, B. M.en_US
dc.contributor.authorAkin, C.en_US
dc.contributor.authorGilfillan, A. M.en_US
dc.date.accessioned2010-06-01T19:13:37Z
dc.date.available2010-06-01T19:13:37Z
dc.date.issued2008-08en_US
dc.identifier.citationJensen, B M; Akin, C; Gilfillan, A M (2008). "Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders." British Journal of Pharmacology 154(8): 1572-1582. <http://hdl.handle.net/2027.42/72410>en_US
dc.identifier.issn0007-1188en_US
dc.identifier.issn1476-5381en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72410
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18500355&dopt=citationen_US
dc.format.extent259973 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2008 British Pharmacological Societyen_US
dc.subject.otherMast Cellsen_US
dc.subject.otherKITen_US
dc.subject.otherMastocytosisen_US
dc.subject.otherAnaphylaxisen_US
dc.subject.otherAllergyen_US
dc.subject.otherTyrosine Kinase Inhibitorsen_US
dc.titlePharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disordersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Allergy and Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherRefLab, National University Hospital, Copenhagen N, Denmarken_US
dc.contributor.affiliationotherLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USAen_US
dc.identifier.pmid18500355en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72410/1/bjp.2008.204.pdf
dc.identifier.doi10.1038/bjp.2008.204en_US
dc.identifier.sourceBritish Journal of Pharmacologyen_US
dc.identifier.citedreferenceAichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF et al. ( 2007 ). Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109: 3031 – 3041.en_US
dc.identifier.citedreferenceAkin C ( 2006 ). Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8: 412 – 419.en_US
dc.identifier.citedreferenceAkin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. ( 2003 ). Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686 – 692.en_US
dc.identifier.citedreferenceAkin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD ( 2004 ). A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103: 3222 – 3225.en_US
dc.identifier.citedreferenceAkin C, Metcalfe DD ( 2004 ). The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114: 13 – 19.en_US
dc.identifier.citedreferenceAkin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al. ( 2007 ). Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with ‘idiopathic’ anaphylaxis. Blood 110: 2331 – 2333.en_US
dc.identifier.citedreferenceAl-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q ( 2004 ). The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 34: 911 – 916.en_US
dc.identifier.citedreferenceAlexeev V, Yoon K ( 2006 ). Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126: 1102 – 1110.en_US
dc.identifier.citedreferenceAndo A, Martin TR, Galli SJ ( 1993 ). Effects of chronic treatment with the c-kit ligand, stem cell factor, on immunoglobulin E-dependent anaphylaxis in mice. Genetically mast cell-deficient Sl/Sld mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses. J Clin Invest 92: 1639 – 1649.en_US
dc.identifier.citedreferenceBayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P ( 2004 ). Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 279: 12249 – 12259.en_US
dc.identifier.citedreferenceBeghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. ( 2000 ). C-kit mutations in core binding factor leukemias. Blood 95: 726 – 727.en_US
dc.identifier.citedreferenceBroudy VC ( 1997 ). Stem cell factor and hematopoiesis. Blood 90: 1345 – 1364.en_US
dc.identifier.citedreferenceBroudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG ( 1994 ). Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83: 2145 – 2152.en_US
dc.identifier.citedreferenceChow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D et al. ( 2007 ). The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines. Leuk Lymphoma 48: 1379 – 1388.en_US
dc.identifier.citedreferenceChow LQ, Eckhardt SG ( 2007 ). Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884 – 896.en_US
dc.identifier.citedreferenceCorbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL et al. ( 2004 ). Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104: 3754 – 3757.en_US
dc.identifier.citedreferenceCosta JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA et al. ( 1996 ). Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183: 2681 – 2686.en_US
dc.identifier.citedreferenceDastych J, Metcalfe DD ( 1994 ). Stem cell factor induces mast cell adhesion to fibronectin. J Immunol 152: 213 – 219.en_US
dc.identifier.citedreferenceDastych J, Taub D, Hardison MC, Metcalfe DD ( 1998 ). Tyrosine kinase-deficient Wv c-kit induces mast cell adhesion and chemotaxis. Am J Physiol 275: C1291 – C1299.en_US
dc.identifier.citedreferenceDorsey JF, Jove R, Kraker AJ, Wu J ( 2000 ). The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 3127 – 3131.en_US
dc.identifier.citedreferenceDroogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL ( 2006 ). Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107: 345 – 351.en_US
dc.identifier.citedreferenceFabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A et al. ( 2000 ). PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15: 17 – 28.en_US
dc.identifier.citedreferenceFlanagan JG, Leder P ( 1990 ). The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63: 185 – 194.en_US
dc.identifier.citedreferenceFlorian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K et al. ( 2005 ). Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 136: 273 – 280.en_US
dc.identifier.citedreferenceFogel WA, Lewinski A, Jochem J ( 2005 ). Histamine in idiopathic inflammatory bowel diseases—not a standby player. Folia Med Cracov 46: 107 – 118.en_US
dc.identifier.citedreferenceFumo G, Akin C, Metcalfe DD, Neckers L ( 2004 ). 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103: 1078 – 1084.en_US
dc.identifier.citedreferenceFuritsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. ( 1993 ). Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 1736 – 1744.en_US
dc.identifier.citedreferenceGabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP et al. ( 2006 ). Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108: 1065 – 1072.en_US
dc.identifier.citedreferenceGalli SJ, Nakae S, Tsai M ( 2005 ). Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135 – 142.en_US
dc.identifier.citedreferenceGarcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. ( 2006 ). KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108: 2366 – 2372.en_US
dc.identifier.citedreferenceGilfillan AM, Tkaczyk C ( 2006 ). Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6: 218 – 230.en_US
dc.identifier.citedreferenceGleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. ( 2006 ). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107: 752 – 759.en_US
dc.identifier.citedreferenceGleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. ( 2007 ). Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92: 1451 – 1459.en_US
dc.identifier.citedreferenceGotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. ( 2005 ). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106: 2865 – 2870.en_US
dc.identifier.citedreferenceGotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C et al. ( 2007 ). The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a Phase II trial. Blood 110: 1035a.en_US
dc.identifier.citedreferenceHantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. ( 2007 ). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104: 13283 – 13288.en_US
dc.identifier.citedreferenceHeinemann A, Sturm GJ, Ofner M, Sturm EM, Weller C, Peskar BA et al. ( 2005 ). Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. J Allergy Clin Immunol 116: 820 – 826.en_US
dc.identifier.citedreferenceHeinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ ( 2000 ). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925 – 932.en_US
dc.identifier.citedreferenceHerbst R, Shearman MS, Jallal B, Schlessinger J, Ullrich A ( 1995 ). Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. Biochemistry 34: 5971 – 5979.en_US
dc.identifier.citedreferenceHirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. ( 1998 ). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577 – 580.en_US
dc.identifier.citedreferenceHochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP et al. ( 2006 ). A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood 108: 764a.en_US
dc.identifier.citedreferenceHollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC ( 2004 ). Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res 120: 288 – 294.en_US
dc.identifier.citedreferenceHongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y et al. ( 2000 ). Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60: 2345 – 2347.en_US
dc.identifier.citedreferenceHuang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW et al. ( 1990 ). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63: 225 – 233.en_US
dc.identifier.citedreferenceIwaki S, Tkaczyk C, Satterthwaite AB, Halcomb K, Beaven MA, Metcalfe DD et al. ( 2005 ). Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit. J Biol Chem 280: 40261 – 40270.en_US
dc.identifier.citedreferenceJensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM ( 2008 ). Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 324: 128 – 138.en_US
dc.identifier.citedreferenceJensen BM, Metcalfe DD, Gilfillan AM ( 2007 ). Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 6: 57 – 62.en_US
dc.identifier.citedreferenceJuurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, Leskinen MJ et al. ( 2005 ). Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 64: 1126 – 1131.en_US
dc.identifier.citedreferenceKapur R, Majumdar M, Xiao X, ndrews-Hill M, Schindler K, Williams DA ( 1998 ). Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood 91: 879 – 889.en_US
dc.identifier.citedreferenceKim MS, Kuehn HS, Metcalfe DD, Gilfillan AM ( 2008 ). Activation and function of the mTORC1 pathway in mast cells. J Immunol 180: 4586 – 4595.en_US
dc.identifier.citedreferenceKirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD ( 1999 ). Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94: 2333 – 2342.en_US
dc.identifier.citedreferenceKitamura Y, Go S ( 1979 ). Decreased production of mast cells in S1/S1d anemic mice. Blood 53: 492 – 497.en_US
dc.identifier.citedreferenceKitamura Y, Go S, Hatanaka K ( 1978 ). Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52: 447 – 452.en_US
dc.identifier.citedreferenceKitamura Y, Oboki K, Ito A ( 2006 ). Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am 26: 387 – 405.en_US
dc.identifier.citedreferenceKitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y ( 1995 ). Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol 107: 54 – 56.en_US
dc.identifier.citedreferenceKitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H et al. ( 1995 ). Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790 – 798.en_US
dc.identifier.citedreferenceKitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J et al. ( 1996 ). Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88: 995 – 1004.en_US
dc.identifier.citedreferenceKlion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. ( 2003 ). Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101: 4660 – 4666.en_US
dc.identifier.citedreferenceKlion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. ( 2004 ). Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473 – 478.en_US
dc.identifier.citedreferenceKojima S, Matsuyama T, Kodera Y ( 1997 ). Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br J Haematol 99: 440 – 446.en_US
dc.identifier.citedreferenceKosmider O, Denis N, Dubreuil P, Moreau-Gachelin F ( 2007 ). Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 26: 3904 – 3908.en_US
dc.identifier.citedreferenceKozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA ( 1998 ). SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 18: 2089 – 2099.en_US
dc.identifier.citedreferenceKuehn HS, Gilfillan AM ( 2007 ). G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett 113: 59 – 69.en_US
dc.identifier.citedreferenceLahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC et al. ( 2008 ). Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93: 49 – 56.en_US
dc.identifier.citedreferenceLawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A et al. ( 2005 ). Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res 572: 1 – 13.en_US
dc.identifier.citedreferenceLennartsson J, Jelacic T, Linnekin D, Shivakrupa R ( 2005 ). Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 16 – 43.en_US
dc.identifier.citedreferenceLev S, Givol D, Yarden Y ( 1992 ). Interkinase domain of kit contains the binding site for phosphatidylinositol 3′ kinase. Proc Natl Acad Sci USA 89: 678 – 682.en_US
dc.identifier.citedreferenceLevitzki A, Mishani E ( 2006 ). Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75: 93 – 109.en_US
dc.identifier.citedreferenceLevy D, Burstein R, Kainz V, Jakubowski M, Strassman AM ( 2007 ). Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130: 166 – 176.en_US
dc.identifier.citedreferenceLinnekin D ( 1999 ). Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31: 1053 – 1074.en_US
dc.identifier.citedreferenceLinnekin D, DeBerry CS, Mou S ( 1997 ). Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 272: 27450 – 27455.en_US
dc.identifier.citedreferenceLiu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. ( 2006 ). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851 – 11858.en_US
dc.identifier.citedreferenceLober K, Alfonso A, Escribano L, Botana LM ( 2008 ). STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. J Cell Biochem 103: 865 – 876.en_US
dc.identifier.citedreferenceLorentz A, Schuppan D, Gebert A, Manns MP, Bischoff SC ( 2002 ). Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood 99: 966 – 972.en_US
dc.identifier.citedreferenceMa Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. ( 2002 ). The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741 – 1744.en_US
dc.identifier.citedreferenceMalone DG, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD ( 1986 ). Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum 29: 956 – 963.en_US
dc.identifier.citedreferenceMalone DG, Metcalfe DD ( 1988 ). Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific IgE and parenteral challenge with specific antigen. Arthritis Rheum 31: 1063 – 1067.en_US
dc.identifier.citedreferenceMalone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD ( 1987 ). Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum 30: 130 – 137.en_US
dc.identifier.citedreferenceMaric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T et al. ( 2007 ). KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 120: 680 – 687.en_US
dc.identifier.citedreferenceMetcalfe DD, Baram D, Mekori YA ( 1997 ). Mast cells. Physiol Rev 77: 1033 – 1079.en_US
dc.identifier.citedreferenceMetcalfe DD, Mekori JA, Rottem M ( 1995 ). Mast cell ontogeny and apoptosis. Exp Dermatol 4: 227 – 230.en_US
dc.identifier.citedreferenceMol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. ( 2004 ). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655 – 31663.en_US
dc.identifier.citedreferenceMol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC et al. ( 2003 ). Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278: 31461 – 31464.en_US
dc.identifier.citedreferenceMuto S, Katsuki M, Horie S ( 2007 ). Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Sci 98: 1549 – 1556.en_US
dc.identifier.citedreferenceNagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. ( 1995 ). Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92: 10560 – 10564.en_US
dc.identifier.citedreferenceNilsson G, Butterfield JH, Nilsson K, Siegbahn A ( 1994 ). Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153: 3717 – 3723.en_US
dc.identifier.citedreferenceOkayama Y, Kawakami T ( 2006 ). Development, migration, and survival of mast cells. Immunol Res 34: 97 – 115.en_US
dc.identifier.citedreferenceOshitani N, Kamata N, Inagawa M, Yamagami H, Watanabe K, Fujiwara Y et al. ( 2006 ). Significance of activated mast cells in submucosa and muscularis propria of patients with Crohn's disease detected by a novel anti-mast cell surface molecule antibody. Aliment Pharmacol Ther 24: 1 – 4.en_US
dc.identifier.citedreferencePan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. ( 2007 ). EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109: 315 – 322.en_US
dc.identifier.citedreferencePardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. ( 2003a ). Imatinib for systemic mast-cell disease. Lancet 362: 535 – 536.en_US
dc.identifier.citedreferencePardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. ( 2003b ). CHIC2 deletion, a surrogate for FIP1L1–PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102: 3093 – 3096.en_US
dc.identifier.citedreferencePardanani A, Reeder T, Li CY, Tefferi A ( 2003c ). Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 27: 883 – 885.en_US
dc.identifier.citedreferencePatnaik MM, Tefferi A, Pardanani A ( 2007 ). Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 7: 492 – 503.en_US
dc.identifier.citedreferencePrenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P et al. ( 2006 ). Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622 – 2627.en_US
dc.identifier.citedreferencePrice DJ, Rivnay B, Fu Y, Jiang S, Avraham S, Avraham H ( 1997 ). Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes. J Biol Chem 272: 5915 – 5920.en_US
dc.identifier.citedreferenceRamanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG et al. ( 2005 ). Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 3385 – 3391.en_US
dc.identifier.citedreferenceReber L, Da Silva CA, Frossard N ( 2006 ). Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533: 327 – 340.en_US
dc.identifier.citedreferenceRivera J, Gilfillan AM ( 2006 ). Molecular regulation of mast cell activation. J Allergy Clin Immunol 117: 1214 – 1225.en_US
dc.identifier.citedreferenceRoskoski Jr R ( 2005a ). Signaling by Kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 337: 1 – 13.en_US
dc.identifier.citedreferenceRoskoski Jr R ( 2005b ). Structure and regulation of Kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 338: 1307 – 1315.en_US
dc.identifier.citedreferenceSamayawardhena LA, Hu J, Stein PL, Craig AW ( 2006 ). Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell Signal 18: 1447 – 1454.en_US
dc.identifier.citedreferenceScheinfeld N ( 2006 ). A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol 5: 117 – 122.en_US
dc.identifier.citedreferenceSchirmer A, Kennedy J, Murli S, Reid R, Santi DV ( 2006 ). Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA 103: 4234 – 4239.en_US
dc.identifier.citedreferenceServe H, Hsu YC, Besmer P ( 1994 ). Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269: 6026 – 6030.en_US
dc.identifier.citedreferenceShah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C ( 2006 ). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286 – 291.en_US
dc.identifier.citedreferenceShivakrupa R, Linnekin D ( 2005 ). Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. Cell Signal 17: 103 – 109.en_US
dc.identifier.citedreferenceSonpavde G, Hutson TE ( 2007 ). Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9: 115 – 119.en_US
dc.identifier.citedreferenceSun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P et al. ( 2007 ). Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13: 719 – 724.en_US
dc.identifier.citedreferenceTanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. ( 2005 ). A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324 – 2331.en_US
dc.identifier.citedreferenceTaylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C et al. ( 2001 ). The Kit-activating mutation D816V enhances stem cell factor—dependent chemotaxis. Blood 98: 1195 – 1199.en_US
dc.identifier.citedreferenceTaylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG et al. ( 2004 ). Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 6: 335 – 342.en_US
dc.identifier.citedreferenceTheoharides TC, Conti P ( 2004 ). Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25: 235 – 241.en_US
dc.identifier.citedreferenceTheoharides TC, Kempuraj D, Iliopoulou BP ( 2007 ). Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 601: 423 – 430.en_US
dc.identifier.citedreferenceThommes K, Lennartsson J, Carlberg M, Ronnstrand L ( 1999 ). Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem J 341 ( Part 1 ): 211 – 216.en_US
dc.identifier.citedreferenceTian Q, Frierson Jr HF, Krystal GW, Moskaluk CA ( 1999 ). Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154: 1643 – 1647.en_US
dc.identifier.citedreferenceTkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson LE, Satterthwaite AB et al. ( 2004 ). NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood 104: 207 – 214.en_US
dc.identifier.citedreferenceTkaczyk C, Jensen BM, Iwaki S, Gilfillan AM ( 2006 ). Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy Clin North Am 26: 427 – 450.en_US
dc.identifier.citedreferenceToksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV et al. ( 1992 ). Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 89: 7350 – 7354.en_US
dc.identifier.citedreferenceTrieselmann NZ, Soboloff J, Berger SA ( 2003 ). Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 60: 759 – 766.en_US
dc.identifier.citedreferenceValent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. ( 2003a ). Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27: 635 – 641.en_US
dc.identifier.citedreferenceValent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. ( 2003b ). Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122: 695 – 717.en_US
dc.identifier.citedreferenceValent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. ( 2001 ). Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603 – 625.en_US
dc.identifier.citedreferencevan Dijk TB, van Den Akker E, Amelsvoort MP, Mano H, Lowenberg B, von Lindern M ( 2000 ). Stem cell factor induces phosphatidylinositol 3′-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood 96: 3406 – 3413.en_US
dc.identifier.citedreferenceVendome J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C et al. ( 2005 ). Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 48: 6194 – 6201.en_US
dc.identifier.citedreferenceVerstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P et al. ( 2006a ). Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30: 1365 – 1370.en_US
dc.identifier.citedreferenceVerstovsek S, Kantarjian H, Cortes J, Ravandi-Kashani F, Borthakur G, Nicaise C et al. ( 2006b ). Dasatinib (Sprycel (TM)) therapy for patients with systemic mastocytosis. Blood 108: 1036a.en_US
dc.identifier.citedreferenceYarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al. ( 1987 ). Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341 – 3351.en_US
dc.identifier.citedreferenceYuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA ( 1997 ). Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 186: 313 – 323.en_US
dc.identifier.citedreferenceZappulla JP, Dubreuil P, Desbois S, Letard S, Hamouda NB, Daeron M et al. ( 2005 ). Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 202: 1635 – 1641.en_US
dc.identifier.citedreferenceZermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N et al. ( 2003 ). Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660 – 664.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjp.2008.204.pdf
Size:
253.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.